Results 131 to 140 of about 306,294 (257)

Incidental renal pelvis and ureteral verrucous carcinoma: A case report and literature review. [PDF]

Medicine (Baltimore)
Yang Z, Liu Y, Zhang X, Song L, Jiang J, Pan J, Li J, Li J.   +7 more
europepmc   +1 more source

Tumor‐Induced Splenic Remodeling: Mechanisms of Systemic Immunosuppression and Emerging Therapeutic Opportunities

Advanced Science, EarlyView.
ABSTRACT Despite the transformative impact of cancer immunotherapies such as immune checkpoint blockade, durable clinical responses remain limited. Increasing evidence indicates that antitumor immunity is governed not only by the tumor microenvironment, but also by systemic immune regulation mediated by peripheral immune organs. Among these, the spleen
Yuehua Liu, Xiaoqian Nie, Xiaofei Gao
wiley   +1 more source

Renal-Type Clear Cell Carcinoma of the Prostate: A Histopathological Case Report of a Rare and Underrecognized Variant. [PDF]

Reports (MDPI)
Stoyanov G, Marchev D, Pavlov P, Popov H.   +3 more
europepmc   +1 more source

Nanozymes for Liver Disease Therapy: Advances in Catalytic Activity, Targeting Strategies, and Clinical Translation

Advanced Science, EarlyView.
Nanozymes, as enzyme‐mimicking nanomaterials, exhibit unique catalytic properties for the treatment of liver diseases. By regulating redox homeostasis, modulating immune responses, and enabling targeted delivery, nanozymes overcome the limitations of natural enzymes.
Xiandi Meng, Ge Zhu, Siyu Sun, Wenbo Yao, Yuning Zhang, Yong‐Guang Yang, Tianmeng Sun   +6 more
wiley   +1 more source

Sarcomatoid Renal Cell Carcinoma: Biological Features and Therapeutic Implications-A Narrative Review. [PDF]

Curr Urol Rep
Lasorsa F, Milella M, Rutigliano M, di Bari A, d'Amati A, Pandolfo SD, Bignante G, Caniglia A, Autorino R, Ditonno P, Lucarelli G.   +10 more
europepmc   +1 more source

Pyroptosis‐Inducing Engineered Microparticles for Cancer Immunotherapy

Advanced Science, EarlyView.
Engineered microparticles co‐delivering geldanamycin and dual nanobodies induce targeted pyroptosis and block PD‐L1 and CD47 pathways, reprogramming the tumor microenvironment and achieving potent antitumor immunity in lung cancer models with minimal toxicity.
Tianli Hao, Zihan Deng, Yufei Liu, Li Liu, Deqiang Deng, Muyang Yang, Yuanyuan Geng, Yao Sun, Beilei Yue, Jonathan F. Lovell, Yushuai Liu, Lisen Lu, Honglin Jin   +12 more
wiley   +1 more source

Renal Clear Cell Carcinoma Discovered Following Pyothorax: A Case Report. [PDF]

Cureus
Benamou A, El Moudane A, Barki A.
europepmc   +1 more source

Association of HAMP Expression and CD8+ T‐Cell Infiltration With Atezolizumab–Bevacizumab Response in Hepatocellular Carcinoma

Annals of Gastroenterological Surgery, EarlyView.
In hepatocellular carcinoma treated with atezolizumab–bevacizumab, responders showed RNA‐seq enrichment of immune and chemokine pathways with higher HAMP expression. In resected specimens, immunohistochemistry confirmed increased intratumoral CD8+ T‐cell density and hepcidin (HAMP), supporting HAMP plus CD8 as components of a composite predictor of ...
Shun Nakamura, Yuki Murakami, Yusuke Oshima, Takashi Masuda, Wataru Miyoshino, Hiroomi Takayama, Yoko Kawano, Teijiro Hirashita, Yuichi Endo, Masafumi Inomata   +9 more
wiley   +1 more source

Identifying Prognostic Biomarkers and Key Pathways in Renal Clear Cell Carcinoma: A Pilot Study Using Integrated miRNA and Gene Expression Analysis. [PDF]

Biochem Res Int
Manoochehri H, Mirzaee K, Taherkhani A, Gholyaf M.   +3 more
europepmc   +1 more source

Real‐World Effectiveness and Safety of Ravulizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria: Evidence From the International PNH Registry

American Journal of Hematology, EarlyView.
ABSTRACT Ravulizumab, a second‐generation complement component 5 inhibitor (C5i) derived from eculizumab, with improved pharmacokinetics, is the current standard‐of‐care treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH), where available.
Alexander Röth, Christopher J. Patriquin, Jeff Szer, Louis Terriou, Ami S. Patel, Jesse Metzger, Philippe Gustovic, Jun‐ichi Nishimura, Robert A. Brodsky   +8 more
wiley   +1 more source